大型HC类II:用免疫检查点抑制剂治疗黑色素瘤的预测结果
Karim Amrane1,2, Pierre Le Noac'h2,3, Patrice Hemon2
1Department of Oncology, Regional Hospital of Morlaix, Morlaix.
Melanoma research
|February 13, 2025
概括
表达MHCII类 (MHC-II) 的黑色素瘤细胞可以预测接受免疫检查点抑制剂 (ICI) 的患者的更好的生存率. 这一发现为转移性皮肤黑色素瘤治疗结果提供了潜在的生物标志物.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
背景情况:
- 转移性皮肤黑色素瘤 (MCM) 构成了重大治疗挑战.
- 免疫检查点抑制剂 (ICI) 改善了结果,但患者的选择仍然至关重要.
- 在MCM中积极寻找ICI反应的预测生物标志物.
研究的目的:
- 评估第一线ICI治疗转移性皮肤黑色素瘤患者在黑色素瘤细胞上的MHC II类 (MHC-II) 表达的预测值.
- 确定MHC-II表达和临床/生物特征之间的相关性.
主要方法:
- 对接受一线ICI的95名IV期皮肤黑色素瘤患者的回顾性分析.
- 在黑色素瘤细胞中通过免疫组织化学 (抗SOX10和抗MHC-II) 来量化MHC-II表达.
- 评估无事件生存率 (EFS),1年EFS,1年总生存率 (OS) 和疾病控制率 (DCR).
主要成果:
- 在6.3%的患者中发现MHC-II阳性 (≥10%的黑色素瘤细胞).
- 大致上,MHC-II表达与改善的1年EFS (P=0.037) 和疾病控制率 (DCR) (P=0.032) 显著相关.
- MHC-II表达与EFS或1年的OS没有显著关联,但与年龄,光型和大脑转移相关.
结论:
- 黑色素瘤细胞的MHC-II表达似乎是治疗ICI的MCM患者生存的有利预测生物标志物.
- 需要进一步的前性研究来验证MHC-II作为黑色素瘤ICI治疗的预测标志物.
相关概念视频
01:26Antigens Involved in Adaptive Immunity
441
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
Complete Antigens
Complete antigens possess both immunogenicity and...
441
01:27Tumor Immunotherapy
464
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
464